Soleno Therapeutics (SLNO) Common Equity: 2013-2019
Historic Common Equity for Soleno Therapeutics (SLNO) over the last 5 years, with Sep 2019 value amounting to $14.9 million.
- Soleno Therapeutics' Common Equity rose 4.79% to $14.9 million in Q3 2019 from the same period last year, while for Sep 2019 it was $14.9 million, marking a year-over-year increase of 4.79%. This contributed to the annual value of $30.4 million for FY2018, which is 13.41% up from last year.
- Latest data reveals that Soleno Therapeutics reported Common Equity of $14.9 million as of Q3 2019, which was up 7.53% from $13.8 million recorded in Q2 2019.
- Over the past 5 years, Soleno Therapeutics' Common Equity peaked at $30.4 million during Q4 2018, and registered a low of -$11.3 million during Q1 2015.
- Over the past 3 years, Soleno Therapeutics' median Common Equity value was $23.2 million (recorded in 2017), while the average stood at $22.1 million.
- Per our database at Business Quant, Soleno Therapeutics' Common Equity spiked by 922.53% in 2017 and then plummeted by 40.66% in 2018.
- Quarterly analysis of 5 years shows Soleno Therapeutics' Common Equity stood at $3.2 million in 2015, then increased by 6.56% to $3.4 million in 2016, then spiked by 680.65% to $26.8 million in 2017, then climbed by 13.41% to $30.4 million in 2018, then rose by 4.79% to $14.9 million in 2019.
- Its Common Equity was $14.9 million in Q3 2019, compared to $13.8 million in Q2 2019 and $23.6 million in Q1 2019.